Sanofi's Evolutive vaccine manufacturing facility will be located in Neuville-sur-Saône, France. Credit: SANOFI.
The new vaccine production facility is expected to create 200 new employment opportunities. Credit: sanofi-aventis France.
The EVF facility is scheduled to be completed in 2025. Credit: Shutterstock

Sanofi is planning to build a new Evolutive vaccine facility (EVF) for the manufacturing of vaccines in Neuville-sur-Saône in the eastern part of France.

EVF facility will allow Sanofi Pasteur, Sanofi’s global vaccine company, to supply vaccines in case of new pandemics.

The investment will boost the company’s capability to further research and mass production of new innovative vaccines.

The project will involve an investment of €490m ($552.4m) over five years and create 200 new job opportunities.

Sanofi’s Evolutive vaccine facility (EVF) location

Sanofi’s Evolutive vaccine manufacturing facility will be located in the Neuville-sur-Saône commune of France.

The Neuville-sur-Saône site is located close to the company’s facility in Marcy-l’Etoile, and Sanofi Pasteur’s global headquarters, as well as the Genzyme production site of Sanofi, situated in the centre of the Sanofi Biotechnology Hub in the city of Lyon.

The company’s existing operations at the facility in Neuville-sur-Saône primarily include biotechnological manufacturing of vaccines. The Neuville-sur-Saône site represents the first dengue vaccine production centre in the world.

In addition, the site includes a research and development (R&D) laboratory devoted to analytical sciences. The plant has high-tech facilities and an innovative structure that enables new vaccines to be developed in collaboration with R&D.

Details of Sanofi’s Evolutive vaccine facility

The state-of-the-art manufacturing facility will incorporate the latest advanced technologies for the manufacturing of vaccines.

EVF is a facility built around a central unit that includes completely digital production modules. The modern factory will be able to produce three to four vaccines at the same time, compared to only one in the existing sites.

Customisation and modular design will enable the development of a specific vaccine on priority and in a more reasonable time frame depending on public health concerns.

Sanofi will work with the European Union (EU) and the French Government to create an additional vaccine or monoclonal antibody (installation of cell culture tanks and start-up projects) manufacturing capabilities for the EU and pharmaceutical firms in case of any healthcare emergency.

Marketing commentary on Sanofi

Sanofi is a major healthcare company delivering solutions and services in more than 170 countries around the world. It plays an instrumental part in meeting customers’ healthcare demands and improving health services.

Through its global vaccines division Sanofi Pasteur, Sanofi is involved in the development and manufacturing of vaccines. The multinational company’s vaccine portfolio includes products to treat patients from infectious diseases, influenza and endemic diseases.

“EVF is a facility built around a central unit that includes completely digital production modules.”

Sanofi Pasteur employs 16,000 personnel and operates 12 vaccine manufacturing sites, including three in France.

It supplies over 200 vaccines, medicines and healthcare-related drug products in France. It has 33 sites in France including 22 industrial sites.

The company has around 5,000 scientists and researchers engaged in therapy areas, with a focus on immuno-oncology, vaccine development, oncology and rare diseases. It is also planning to spend €120m ($135.3m) to set up a new research and development facility in France at Sanofi Pasteur’s Marcy-l’Etoile site to produce possible future vaccines.

The proposed advanced digital facility in Marcy-l’Etoile will be equipped with specialised laboratories for vaccine development against emerging diseases and pandemic hazards.

Sanofi aims to transform its French operations into a centre of excellence in the areas of vaccine research and manufacturing.

The company is also supporting global efforts to combat the Covid-19 pandemic disease. It joined forces with GSK to explore the use of recombinant DNA technology to produce a potential Covid-19 vaccine. Its research efforts, in partnership with TranslateBio, are focused on developing a vaccine using messenger RNA technology.